Cargando…

Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach

Breast cancer (BC) is a heterogeneous disease representing a substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need to be fully understood. Evidence suggests that early-stage BC has a lower cost than a late stage BC. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Shah Alam, Hernandez-Villafuerte, Karla, Hernandez, Diego, Schlander, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853539/
https://www.ncbi.nlm.nih.gov/pubmed/36684975
http://dx.doi.org/10.3389/fpubh.2022.946544
_version_ 1784872924521431040
author Khan, Shah Alam
Hernandez-Villafuerte, Karla
Hernandez, Diego
Schlander, Michael
author_facet Khan, Shah Alam
Hernandez-Villafuerte, Karla
Hernandez, Diego
Schlander, Michael
author_sort Khan, Shah Alam
collection PubMed
description Breast cancer (BC) is a heterogeneous disease representing a substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need to be fully understood. Evidence suggests that early-stage BC has a lower cost than a late stage BC. We aim to provide conservative estimates of BC's stage-wise medical costs from German healthcare and the payer's perspective. To this end, we conducted a literature review of articles evaluating stage-wise costs of BC in Germany through PubMed, Web of Science, and Econ Lit databases supplemented by Google Scholar. We developed a decision tree model to estimate BC-related medical costs in Germany using available treatment and cost information. The review generated seven studies; none estimated the stage-wise costs of BC. The studies were classified into two groups: case scenarios (five studies) and two studies based on administrative data. The first sickness funds data study (Gruber et al., 2012) used information from the year 1999 to approach BC attributable cost; their results suggest a range between €3,929 and €11,787 depending on age. The second study (Kreis, Plöthner et al., 2020) used 2011–2014 data and suggested an initial phase incremental cost of €21,499, an intermediate phase cost of €2,620, and a terminal phase cost of €34,513 per incident case. Our decision tree model-based BC stage-wise cost estimates were €21,523 for stage I, €25,679 for stage II, €30,156 for stage III, and €42,086 for stage IV. Alternatively, the modeled cost estimates are €20,284 for the initial phase of care, €851 for the intermediate phase of care, and €34,963 for the terminal phase of care. Our estimates for phases of care are consistent with recent German estimates provided by Kreis et al. Furthermore, the data collected by sickness funds are collected primarily for reimbursement purposes, where the German ICD-10 classification system defines a cancer diagnosis. As a result, claims data lack the clinical information necessary to understand stage-wise BC costs. Our model-based estimates fill the gap and inform future economic evaluations of BC interventions.
format Online
Article
Text
id pubmed-9853539
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98535392023-01-21 Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach Khan, Shah Alam Hernandez-Villafuerte, Karla Hernandez, Diego Schlander, Michael Front Public Health Public Health Breast cancer (BC) is a heterogeneous disease representing a substantial economic burden. In order to develop policies that successfully decrease this burden, the factors affecting costs need to be fully understood. Evidence suggests that early-stage BC has a lower cost than a late stage BC. We aim to provide conservative estimates of BC's stage-wise medical costs from German healthcare and the payer's perspective. To this end, we conducted a literature review of articles evaluating stage-wise costs of BC in Germany through PubMed, Web of Science, and Econ Lit databases supplemented by Google Scholar. We developed a decision tree model to estimate BC-related medical costs in Germany using available treatment and cost information. The review generated seven studies; none estimated the stage-wise costs of BC. The studies were classified into two groups: case scenarios (five studies) and two studies based on administrative data. The first sickness funds data study (Gruber et al., 2012) used information from the year 1999 to approach BC attributable cost; their results suggest a range between €3,929 and €11,787 depending on age. The second study (Kreis, Plöthner et al., 2020) used 2011–2014 data and suggested an initial phase incremental cost of €21,499, an intermediate phase cost of €2,620, and a terminal phase cost of €34,513 per incident case. Our decision tree model-based BC stage-wise cost estimates were €21,523 for stage I, €25,679 for stage II, €30,156 for stage III, and €42,086 for stage IV. Alternatively, the modeled cost estimates are €20,284 for the initial phase of care, €851 for the intermediate phase of care, and €34,963 for the terminal phase of care. Our estimates for phases of care are consistent with recent German estimates provided by Kreis et al. Furthermore, the data collected by sickness funds are collected primarily for reimbursement purposes, where the German ICD-10 classification system defines a cancer diagnosis. As a result, claims data lack the clinical information necessary to understand stage-wise BC costs. Our model-based estimates fill the gap and inform future economic evaluations of BC interventions. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9853539/ /pubmed/36684975 http://dx.doi.org/10.3389/fpubh.2022.946544 Text en Copyright © 2023 Khan, Hernandez-Villafuerte, Hernandez and Schlander. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Khan, Shah Alam
Hernandez-Villafuerte, Karla
Hernandez, Diego
Schlander, Michael
Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title_full Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title_fullStr Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title_full_unstemmed Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title_short Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach
title_sort estimation of the stage-wise costs of breast cancer in germany using a modeling approach
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853539/
https://www.ncbi.nlm.nih.gov/pubmed/36684975
http://dx.doi.org/10.3389/fpubh.2022.946544
work_keys_str_mv AT khanshahalam estimationofthestagewisecostsofbreastcanceringermanyusingamodelingapproach
AT hernandezvillafuertekarla estimationofthestagewisecostsofbreastcanceringermanyusingamodelingapproach
AT hernandezdiego estimationofthestagewisecostsofbreastcanceringermanyusingamodelingapproach
AT schlandermichael estimationofthestagewisecostsofbreastcanceringermanyusingamodelingapproach